UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
0.9820 x 21 0.9900 x 5
Post-market by (Cboe BZX)
0.9941 +0.0241 (+2.48%) 04/22/25 [NASDAQ]
0.9820 x 21 0.9900 x 5
Post-market 0.9941 unch (unch) 16:00 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9525
Day High
0.9979
Open 0.9700
Previous Close 0.9700 0.9700
Volume 60,714 60,714
Avg Vol 226,851 226,851
Stochastic %K 66.99% 66.99%
Weighted Alpha -55.99 -55.99
5-Day Change -0.0359 (-3.49%) -0.0359 (-3.49%)
52-Week Range 0.7709 - 3.1200 0.7709 - 3.1200
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,131
  • Shares Outstanding, K 82,609
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,770 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.62
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.37
  • Most Recent Earnings $-0.07 on 03/31/25
  • Next Earnings Date 05/13/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 594.68% ( +263.56%)
  • Historical Volatility 76.94%
  • IV Percentile 95%
  • IV Rank 46.61%
  • IV High 1,206.81% on 01/15/25
  • IV Low 60.32% on 06/04/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,535
  • Open Int (30-Day) 2,514

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7709 +28.95%
on 04/07/25
Period Open: 1.1200
1.1837 -16.02%
on 03/24/25
-0.1259 (-11.24%)
since 03/21/25
3-Month
0.7709 +28.95%
on 04/07/25
Period Open: 1.3200
1.5100 -34.17%
on 02/06/25
-0.3259 (-24.69%)
since 01/22/25
52-Week
0.7709 +28.95%
on 04/07/25
Period Open: 1.7600
3.1200 -68.14%
on 06/12/24
-0.7659 (-43.52%)
since 04/22/24

Most Recent Stories

More News
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Designed to assess the impact of CardiolRxâ„¢ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase...

CRDL.TO : 1.36 (+3.03%)
CRDL : 0.9941 (+2.48%)
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory...

CRDL.TO : 1.36 (+3.03%)
CRDL : 0.9941 (+2.48%)
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failureToronto, Ontario--(Newsfile...

CRDL.TO : 1.36 (+3.03%)
CRDL : 0.9941 (+2.48%)
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 1.36 (+3.03%)
CRDL : 0.9941 (+2.48%)
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

For Immediate ReleaseChicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR...

CORT : 64.68 (+2.83%)
DYN : 9.91 (+6.22%)
CRDL : 0.9941 (+2.48%)
AMRX : 7.25 (+1.68%)
NKTR : 0.6640 (+6.09%)
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency...

CORT : 64.68 (+2.83%)
DYN : 9.91 (+6.22%)
CRDL : 0.9941 (+2.48%)
AMRX : 7.25 (+1.68%)
NKTR : 0.6640 (+6.09%)
3 Penny Stocks Ready to Break Out in 2025

Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.

VUZI : 1.6600 (+3.75%)
CRDL : 0.9941 (+2.48%)
GOVX : 0.8179 (+7.60%)
Buy the Dip: 2 Cannabis ETFs Set to Benefit from Business-Friendly Policies

The recent appointment of Matt Gaetz as Attorney General has sparked controversy - and a surge in cannabis stocks. Two ETFs, AdvisorShares Pure Cannabis ETF (YOLO) and AdvisorShares Pure US Cannabis ETF...

YOLO : 1.7600 (+4.76%)
CURLF : 0.8875 (+4.00%)
SNDL : 1.3900 (+2.21%)
HITI : 2.29 (-0.87%)
VFF : 0.6397 (+4.90%)
CRLBF : 0.6532 (+3.67%)
CRDL : 0.9941 (+2.48%)
TCNNF : 3.8955 (+4.16%)
VRNOF : 0.6400 (+10.34%)
GTBIF : 5.3600 (+2.68%)
MSOS : 2.42 (+3.86%)
Stocks in play: Cardiol Therapeutics Inc.

Reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact ...

CRDL : 0.9941 (+2.48%)
Five Top Heart Health Stocks to Buy Heading into 2025

Heart health statistics are startling. Not only is heart disease the leading cause of death in the United States, it also claims the life of one person every 33 seconds. Plus, the estimated global annual...

ABT : 131.73 (+1.42%)
BSX : 95.05 (+1.57%)
CRDL : 0.9941 (+2.48%)
GILD : 105.51 (+1.13%)
MDT : 83.37 (+1.92%)

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 1.0559
2nd Resistance Point 1.0269
1st Resistance Point 1.0105
Last Price 0.9941
1st Support Level 0.9651
2nd Support Level 0.9361
3rd Support Level 0.9197

See More

52-Week High 3.1200
Fibonacci 61.8% 2.2226
Fibonacci 50% 1.9454
Fibonacci 38.2% 1.6683
Last Price 0.9941
52-Week Low 0.7709

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro